Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).
Victor Gonzalez, MD
Advertisement
Articles by Victor Gonzalez, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Modern Retina
1
Leadership in action during the 2025 AAO named lectures
2
AAO 2025: Ashkan Abbey on the outcomes of EYP-1901 for AMD and DME
3
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
4
Empowerment through education: Q&A with Inder Paul Singh, MD
5
